- CEO
- Hao Zhang
- Full Time Employees
- 2,475
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Jinsha Community Shenzhen GD China 518122
- IPO Date
- Apr 12, 2011
- Business
- Edan Instruments, Inc. Edan Instruments, Inc. engages in the research, development, manufacture, and service of medical electronic equipment and in vitro diagnostic products principally in China and internationally. Founded in 1995 and headquartered in Shenzhen, China, the company offers a comprehensive portfolio of core products and solutions across patient monitoring, including modular and compact patient monitors, vital signs monitors, telemetry systems, and IT integration products; electrocardiogram (ECG) diagnosis, encompassing resting ECG, stress test, Holter monitoring, wireless solutions, and ECG workstations; obstetrics and gynecology devices, such as fetal and maternal monitoring systems, fetal telemetry, ultrasonic Doppler systems, central monitoring stations, video colposcopes, and biofeedback/stimulation systems; ultrasound imaging systems comprising cart-based color Doppler, portable color Doppler, and black-and-white ultrasound; in-vitro diagnostics featuring hematology analyzers and reagents; point-of-care testing with blood gas and chemistry analyzers, molecular diagnostic systems, disposable arterial blood samplers, and blood gas capillary tubes; as well as veterinary ultrasound, ECG, laboratory, and monitoring products. Edan Instruments operates globally, serving customers in over 120 countries through subsidiaries and facilities including EDAN Diagnostics, Inc. in San Diego, California; EDAN Instruments GmbH in Germany; and entities in France, Indonesia, Peru, Thailand, Kenya, the United Kingdom, Russia, and India. Among its latest major developments, the company opened a new U.S. manufacturing hub in San Diego on September 30, 2025, integrating production, logistics, R&D, and support to enhance North American supply chain resilience; entered a collaboration with Global Health Labs in March 2024 to co-develop AI-enabled ultrasound devices targeting low- and middle-income countries; announced the acquisition by EDAN Diagnostics of a molecular diagnostic point-of-care platform from LGC, including ongoing assay development partnerships; and launched innovations such as the iV100 patient monitor and advanced clinical care devices at the 2025 China International Medical Equipment Fair.